Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
CB-06036 by Shanghai Zhimeng Biopharma for Hepatitis B: Likelihood of Approval
CB-06036 is under clinical development by Shanghai Zhimeng Biopharma and currently in Phase I for Hepatitis B. According to GlobalData,...